睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 35 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 35

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心广州医科大学附属肿瘤医院Affiliated Cancer Hospital of Guangzhou Medical University广州医院页面
  2. 研究中心西南医科大学附属医院Affiliated Hospital of Southwest Medical University泸州医院页面
  3. 研究中心徐州医科大学附属医院Affiliated Hospital of Xuzhou Medical University徐州医院页面
  4. 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
  5. 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
  6. 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面
  7. 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
  8. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  9. 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
  10. 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
  11. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  12. 研究中心河南医药大学第一附属医院First Affiliated Hospital of Xinxiang Medical University新乡医院页面
  13. 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  14. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  15. 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
  16. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  17. 研究中心广东省人民医院Guangdong Provincial People's Hospital广州医院页面
  18. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  19. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  20. 研究中心河南省人民医院Henan Provincial People's Hospital郑州医院页面
  21. 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
  22. 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
  23. 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
  24. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  25. 研究中心北京大学人民医院Peking University People's Hospital北京医院页面
  26. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  27. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面
  28. 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
  29. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  30. 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
  31. 研究中心中南大学湘雅三医院Third Xiangya Hospital长沙医院页面
  32. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  33. 研究中心四川大学华西医院West China Hospital成都医院页面
  34. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面
  35. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07217301,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. (a) Squamous NSCLC: Have locally unresectable advanced or metastatic histologically or cytologically confirmed squamous NSCLC. Mixed small cell carcinoma, or other pathological components are excluded.

    入选标准第 3 条

  3. Received prior platinum-based chemotherapy with or without radiotherapy with maintenance anti-PD-1/PD-L1 therapy for Stage III disease and radiographic recurrence/progression within 6 months from the last dose of platinum-based chemotherapy. OR

    入选标准第 8 条

    Received prior peri-operative platinum-based chemotherapy with maintenance anti-PD-1/PD-L1 therapy for resectable Stage II/III and have radiographic recurrence within 6 months from the last dose of platinum-based chemotherapy.

    入选标准第 9 条

  4. Have had radiographic disease progression on or after prior treatment with anti-PD-1/PD-L1 therapy and platinum-based doublet chemotherapy (for example, carboplatin and paclitaxel), given either concurrently or sequentially. A total exposure of >=6 weeks of prior anti-PD-1/PD-L1 therapy is required. Eligible participants include those that have:

    入选标准第 4 条

    Received platinum-based chemotherapy in combination with anti-PD-1/PD-L1 therapy as only prior line of therapy. OR

    入选标准第 5 条

    Received platinum-based chemotherapy and anti-PD-1/PD-L1 therapy sequentially (in either order) as the only 2 prior lines of therapy.

    入选标准第 6 条

    Participants who have received prior anti-PD-1/PD-L1 therapy with curative intent for locally advanced disease are eligible if they meet either of the following criteria:

    入选标准第 7 条

    ECOG performance status (PS) score of 0 or 1. 9. Expected survival time >=3 months. 10. WOCBP must take a urine or serum pregnancy test, highly sensitive tests are required where available based on region and must test negative for trial inclusion. WOCBP must agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception during the entire course of treatment and for 6 months after the last dose of trial treatment. Fertile men must agree to use a condom, preferably combined with at least 1 form of acceptable contraception for any WOCBP partner(s) during the entire course of treatment and for 6 months after the last dose of trial intervention.

    入选标准第 12 条

    Lactating women must agree to strictly abstain from breastfeeding during the entire Treatment Period and for 6 months after the treatment.

    入选标准第 13 条

    Have not adequately recovered from previous surgery or have undergone any major surgery, within 4 weeks before the first dose of investigational product.

    排除标准第 54 条

    Participants who have received definitive HCV treatment and have undetectable viral load results are allowed.

    排除标准第 61 条

    Received more than 1 anti-PD-1/PD-L1 therapy in metastatic or recurrent unresectable locally advanced setting. Prior anti-PD-1/PD-L1 therapy in the curative locally advanced setting followed by anti-PD-1/PD-L1 therapy in the metastatic or recurrent unresectable locally advanced setting is allowed, not to exceed 2 prior lines of anti-PD-1/PD-L1 therapy in total.

    排除标准第 69 条

    One prior line of anti-VEGF antibody administered in combination with 1L ICI and chemotherapy is allowed.

    排除标准第 71 条

    For participants with KRAS mutations, 1 prior line of RAS-targeted therapy is allowed.

    排除标准第 72 条

  5. EGFR: including exon 19 deletion, exon 21 L858R, exon 20 T790M, exon 20 S768I, exon 21 L861Q, exon 18 G719X, and exon 20 insertion mutations.

    排除标准第 3 条

    EGFR: including exon 19 deletion, exon 21 L858R, exon 20 T790M, exon 20 S768I, exon 21 L861Q, exon 18 G719X, and exon 20 insertion mutations.

    排除标准第 11 条

    Hemoglobin <9 g/dL.

    排除标准第 17 条

    Absolute neutrophil count (ANC) <1,500 mm\^3.

    排除标准第 18 条

    Total bilirubin greater than (>) 1.0×ULN except for participants with Gilbert's syndrome with serum bilirubin <=3×ULN or if concurrent conjugated bilirubin <=ULN.

    排除标准第 21 条

    AST or ALT >2.5×ULN without concomitant alkaline phosphatase >2.5×ULN or AST or ALT >1.5×ULN with concomitant alkaline phosphatase >2.5×ULN. For participants with liver metastases, AST or ALT >5×ULN (alkaline phosphatase must be <=2.5×ULN).

    排除标准第 22 条

    Creatinine clearance (CrCl) <30 milliliters per minute (mL/min); the Cockcroft-Gault formula is used to calculate CrCl (using ideal body weight for obese participants and actual body weight for non-obese participants).

    排除标准第 23 条

    International normalized ratio (INR) >1.5×ULN (>3×ULN if on stable dose anticoagulation).

    排除标准第 26 条

    Partial thromboplastin time (PTT; or activated partial thromboplastin time [aPTT]) >1.5×ULN (>3×ULN if on stable-dose anticoagulation).

    排除标准第 27 条

  6. Participants who are HIV-positive must have CD4 >=350 cells per microliter (cells/µL) and must be on established highly active antiretroviral therapy (ensure no expected drug-drug interactions) for at least 4 weeks with an HIV viral load <400 copies/mL).

    排除标准第 57 条

    Participants with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) should undergo HBV DNA testing. If the HBV DNA copy number is <=2.5×10\^3 copies/mL or <=500 IU/mL) or below the lower limit of detection, the participant can be enrolled.

    排除标准第 59 条

    Participants with positive HCV serology results must have an HCV RNA viral load that is negative or below the lower limit of detection.

    排除标准第 60 条

    Diagnosed with other pathologically confirmed malignancies within 5 years prior to informed consent, with exception of radically treated basal cell carcinoma of skin, squamous cell carcinoma of skin, carcinoma in situ, localized prostate cancer, papillary thyroid cancer, and other radically treated malignancies with no known active disease for at least 2 years prior to enrollment and with very low risk of recurrence.

    排除标准第 66 条

  7. Women who are pregnant or breastfeeding, or intending to become pregnant before, during, or within 6 months after the last dose of any trial intervention. WOCBP not using and/or not willing to use at least 1 form of highly effective method of contraception and 1 barrier method of contraception or fertile men with WOCBP partner(s) not using and/or not willing to use at least 1 form of acceptable contraception.

    排除标准第 1 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07217301,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Must be able to understand and willing to sign the written ICF and be able to comply with the visit schedule and related procedures specified in the protocol.
  2. Male or female participants must be at least 18 years old or the legal age of majority in their country, whichever is greater. Note: For the Japan-specific SRI part, participants must be Japanese residing in Japan.
  3. (a) Squamous NSCLC: Have locally unresectable advanced or metastatic histologically or cytologically confirmed squamous NSCLC. Mixed small cell carcinoma, or other pathological components are excluded.
  4. Have had radiographic disease progression on or after prior treatment with anti-PD-1/PD-L1 therapy and platinum-based doublet chemotherapy (for example, carboplatin and paclitaxel), given either concurrently or sequentially. A total exposure of >=6 weeks of prior anti-PD-1/PD-L1 therapy is required. Eligible participants include those that have:
  5. Received platinum-based chemotherapy in combination with anti-PD-1/PD-L1 therapy as only prior line of therapy. OR
  6. Received platinum-based chemotherapy and anti-PD-1/PD-L1 therapy sequentially (in either order) as the only 2 prior lines of therapy.
  7. Participants who have received prior anti-PD-1/PD-L1 therapy with curative intent for locally advanced disease are eligible if they meet either of the following criteria:
  8. Received prior platinum-based chemotherapy with or without radiotherapy with maintenance anti-PD-1/PD-L1 therapy for Stage III disease and radiographic recurrence/progression within 6 months from the last dose of platinum-based chemotherapy. OR
  9. Received prior peri-operative platinum-based chemotherapy with maintenance anti-PD-1/PD-L1 therapy for resectable Stage II/III and have radiographic recurrence within 6 months from the last dose of platinum-based chemotherapy.
  10. Provide formalin-fixed tumor tissue specimen. Fresh biopsies are preferred but archival specimens collected within 2 years before signing the informed consent form are acceptable (blocks or 10-15 unstained slides sectioned 4-5 microns in thickness, if tissue slides, they must be sectioned from blocks <= 2 months from date of consent). FFPE blocks are preferred for submission; slides should be sent only if there is a local regulation preventing submission of the FFPE block. Ideally, the archival specimen should be collected subsequent to the most recent systemic therapy.
  11. Have at least 1 measurable lesion (target lesion) by CT or MRI according to RECIST V1.1. Lesions that have previously received radiotherapy or intratumoral injection can only be used as measurable lesions if they show progression after treatment (either pathologically confirmed or with observation of radiographic progression more than 3 months after treatment) as per RECIST V1.1. Lesions chosen for a screening biopsy should not be designated as target lesions, unless pretreatment baseline imaging is performed at least 2 weeks after the biopsy to allow for adequate healing.
  12. ECOG performance status (PS) score of 0 or 1. 9. Expected survival time >=3 months. 10. WOCBP must take a urine or serum pregnancy test, highly sensitive tests are required where available based on region and must test negative for trial inclusion. WOCBP must agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception during the entire course of treatment and for 6 months after the last dose of trial treatment. Fertile men must agree to use a condom, preferably combined with at least 1 form of acceptable contraception for any WOCBP partner(s) during the entire course of treatment and for 6 months after the last dose of trial intervention.
  13. Lactating women must agree to strictly abstain from breastfeeding during the entire Treatment Period and for 6 months after the treatment.

排除标准:Exclusion Criteria:

  1. Women who are pregnant or breastfeeding, or intending to become pregnant before, during, or within 6 months after the last dose of any trial intervention. WOCBP not using and/or not willing to use at least 1 form of highly effective method of contraception and 1 barrier method of contraception or fertile men with WOCBP partner(s) not using and/or not willing to use at least 1 form of acceptable contraception.
  2. (a) Squamous NSCLC: Known actionable genomic alteration, including any of the following driver gene mutations:
  3. EGFR: including exon 19 deletion, exon 21 L858R, exon 20 T790M, exon 20 S768I, exon 21 L861Q, exon 18 G719X, and exon 20 insertion mutations.
  4. ALK rearrangement.
  5. ROS proto-oncogene 1, ROS1 rearrangement.
  6. B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation.
  7. NTRK 1/2/3 fusion.
  8. MET proto-oncogene, MET exon 14 skipping mutation.
  9. RET proto-oncogene (RET) rearrangement.
  10. V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, also known as HER2) mutation.
  11. EGFR: including exon 19 deletion, exon 21 L858R, exon 20 T790M, exon 20 S768I, exon 21 L861Q, exon 18 G719X, and exon 20 insertion mutations.
  12. ALK rearrangement.
  13. ROS1 rearrangement.
  14. Any other driver gene mutations listed here are excluded if known to be present, but routine testing for these or other known actionable genomic alterations is not required: BRAF V600E mutation; NTRK 1/2/3 fusion; MET exon 14 skipping mutation; RET rearrangement; and ERBB2, also known as HER2 mutation.
  15. Participants with enlarging or symptomatic brain metastases are excluded from the trial. Participants who are neurologically, clinically and radiologically stable >=2 weeks after definitive treatment for brain metastases and/or participants with small (sum of all brain lesions: ≤3 cm), asymptomatic, incidental, untreated brain metastases may participate in this trial as long as they meet certain criteria as defined in the protocol.
  16. Presence of any of the following hematologic abnormalities at baseline*:
  17. Hemoglobin <9 g/dL.
  18. Absolute neutrophil count (ANC) <1,500 mm\^3.
  19. PLT count <100 x 10\^3/mm\^3. *"Baseline" is defined as the last available observation prior to the first dose of investigational product.
  20. Presence of any of the following serum chemistry abnormalities at baseline:
  21. Total bilirubin greater than (>) 1.0×ULN except for participants with Gilbert's syndrome with serum bilirubin <=3×ULN or if concurrent conjugated bilirubin <=ULN.
  22. AST or ALT >2.5×ULN without concomitant alkaline phosphatase >2.5×ULN or AST or ALT >1.5×ULN with concomitant alkaline phosphatase >2.5×ULN. For participants with liver metastases, AST or ALT >5×ULN (alkaline phosphatase must be <=2.5×ULN).
  23. Creatinine clearance (CrCl) <30 milliliters per minute (mL/min); the Cockcroft-Gault formula is used to calculate CrCl (using ideal body weight for obese participants and actual body weight for non-obese participants).
  24. Albumin <30 grams per liter (g/L).
  25. Presence of any of the following coagulation parameter abnormalities at baseline:
  26. International normalized ratio (INR) >1.5×ULN (>3×ULN if on stable dose anticoagulation).
  27. Partial thromboplastin time (PTT; or activated partial thromboplastin time [aPTT]) >1.5×ULN (>3×ULN if on stable-dose anticoagulation).
  28. History of deep venous thrombosis, pulmonary embolism, or any other serious thromboembolic events within 30 days prior to enrollment (implantable port or catheter-related thrombosis, or superficial venous thrombosis are not considered "serious" thromboembolisms). Participants with a history of a serious thromboembolic event must be asymptomatic and on stable anticoagulation therapy (if such therapy is deemed necessary by the treating physician).
  29. Active uncontrolled bleeding, known bleeding diathesis, or significant concern for risk of acute life-threatening bleeding (for example, radiographic evidence that tumor invades large blood vessels or the investigator judges that the tumor is very likely to invade major vessels with the potential to cause fatal bleeding during the duration of the trial).
  30. Presence of clinically significant cardiovascular or cerebrovascular diseases, including:
  31. Symptomatic, clinically unstable arrhythmia or arrhythmia requiring clinical intervention.
  32. Severe conduction disorders (such as third-degree atrioventricular block and bundle branch block).
  33. QT interval corrected for heart rate (QTc interval, calculated using Fridericia's formula) >=480 msec.
  34. Uncontrolled hypertension despite standard treatment.
  35. History of myocarditis.
  36. Left ventricular ejection fraction <50%.
  37. Congestive heart failure requiring treatment.
  38. Class II to IV cardiac insufficiency according to the New York Heart Association functional classification.
  39. History of acute coronary syndrome (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to the first dose of investigational product.
  40. Cerebrovascular accident or transient ischemic attack within 6 months before the first dose of the investigational product.
  41. History of seizures unless controlled on stable dose of antiseizure medications.
  42. Cardiac enzymes >=levels consistent with acute myocardial infarction as defined by laboratory-specific criteria. Participants with isolated Grade 1 elevated cardiac enzymes require cardiology clearance and consultation with the sponsor's medical monitor to confirm absence of ongoing myocardial/ischemic disease.
  43. History of or current ILD; history or current presence of the following lung diseases requiring corticosteroid therapy: pulmonary fibrosis, and drug-related, immune-related or radiation pneumonitis; current active pulmonary infection requiring anti-infective therapy; active pulmonary TB within 1 year prior to enrollment; severely impaired pulmonary function, including but not limited to the following:, severe asthma or severe chronic obstructive pulmonary disease within 3 months prior to randomization; autoimmune, connective tissue, or inflammatory diseases involving the lungs (such as rheumatoid arthritis, Sjögren's disease, and sarcoidosis); previous unilateral pneumonectomy.
  44. History of severe, poorly controlled allergies, asthma or atopic dermatitis (except for atopic dermatitis caused by immunotherapy).
  45. Uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, abdominal effusion, or pericardial effusion.
  46. Current or recent significant gastrointestinal disease or condition, including:
  47. Flare of inflammatory bowel disease (within 6 months prior to the first dose of the investigational product).
  48. Grade >=2 diarrhea CTCAE V5.0 within 2 weeks prior to the first dose of the investigational product.
  49. Active autoimmune disease requiring systemic treatment (for example, use of disease modifying drugs, corticosteroids >10 milligrams (mg) daily equivalent of prednisone, biologics or immunosuppressants) within 2 years before the first dose.
  50. Known history of allogeneic organ transplantation and/or allogeneic hematopoietic stem cell transplantation.
  51. Known or suspected allergy to the investigational product and any excipients. Known or suspected severe hypersensitivity reactions to docetaxel or to drugs formulated with polysorbate 80.
  52. Prior history of significant toxicity related to ICI administration that required permanent discontinuation of this therapy.
  53. Unresolved Grade >1 toxicity related to any previous antitumor therapy (excluding alopecia, asthenia, hypothyroidism requiring only thyroid hormone replacement therapy (HRT), hyperglycemia requiring only insulin replacement therapy, adrenal insufficiency requiring physiological corticosteroid replacement, electrolyte abnormalities requiring only symptomatic treatment, and other conditions not affecting the investigational product treatment as assessed by the investigator).
  54. Have not adequately recovered from previous surgery or have undergone any major surgery, within 4 weeks before the first dose of investigational product.
  55. Uncontrolled tumor-related pain or symptomatic hypercalcemia.
  56. Uncontrolled human immunodeficiency virus (HIV), active syphilis, active hepatitis B virus (HBV), or hepatitis C virus (HCV).
  57. Participants who are HIV-positive must have CD4 >=350 cells per microliter (cells/µL) and must be on established highly active antiretroviral therapy (ensure no expected drug-drug interactions) for at least 4 weeks with an HIV viral load <400 copies/mL).
  58. Participants with positive results consistent with an untreated syphilis infection cannot enroll.
  59. Participants with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) should undergo HBV DNA testing. If the HBV DNA copy number is <=2.5×10\^3 copies/mL or <=500 IU/mL) or below the lower limit of detection, the participant can be enrolled.
  60. Participants with positive HCV serology results must have an HCV RNA viral load that is negative or below the lower limit of detection.
  61. Participants who have received definitive HCV treatment and have undetectable viral load results are allowed.
  62. Serious/active/uncontrolled infection, infection requiring systemic intravenous antibiotics, or fever of unknown origin (>=38°C) within 2 weeks before the first dose of investigational product.
  63. History or current evidence of any disease, treatment, or laboratory abnormality that, in the judgment of the investigator, could compromise the safety of the participant, interfere with obtaining informed consent, affect participant compliance, or affect safety evaluations of the investigational product.
  64. Psychiatric illness altered mental status, or drug abuse that prevents understanding of the informed consent process and/or completion of required trial-related evaluations.
  65. Unable to meet protocol requirements for known or foreseeable reasons per investigator judgement.
  66. Diagnosed with other pathologically confirmed malignancies within 5 years prior to informed consent, with exception of radically treated basal cell carcinoma of skin, squamous cell carcinoma of skin, carcinoma in situ, localized prostate cancer, papillary thyroid cancer, and other radically treated malignancies with no known active disease for at least 2 years prior to enrollment and with very low risk of recurrence.
  67. Received any of following excluded medications or treatments:
  68. Docetaxel.
  69. Received more than 1 anti-PD-1/PD-L1 therapy in metastatic or recurrent unresectable locally advanced setting. Prior anti-PD-1/PD-L1 therapy in the curative locally advanced setting followed by anti-PD-1/PD-L1 therapy in the metastatic or recurrent unresectable locally advanced setting is allowed, not to exceed 2 prior lines of anti-PD-1/PD-L1 therapy in total.
  70. Systemic antitumor therapy except anti-PD-1/PD-L1 therapy and platinum-based doublet chemotherapy including but not limited to targeted therapy, antibody drug conjugates, cell therapies, and other ICIs.
  71. One prior line of anti-VEGF antibody administered in combination with 1L ICI and chemotherapy is allowed.
  72. For participants with KRAS mutations, 1 prior line of RAS-targeted therapy is allowed.
  73. Interleukin (IL)-2 or IL-15 cytokines or related therapies.
  74. Chemotherapy within 2 weeks or 5 half-lives (whichever is longer) before the first dose of investigational product without delayed toxicity.
  75. Antitumor antibody therapy (excluding antibody drugs such as denosumab for the treatment of bone metastases) within 4 weeks before first dose of the investigational product.
  76. Palliative radiotherapy within 2 weeks prior to the first dose of investigational product.
  77. Live vaccine within 28 days prior to first dose of investigational product.
  78. Immunosuppressive or systemic corticosteroid therapy (>10 mg/day of prednisone or equivalent) within 2 weeks prior to the first dose of investigational product.
  79. Received traditional Chinese medicine with potential antitumor activity or known antitumor indications within 1 week before the first dose of the investigational product.

引自 ClinicalTrials.gov, NCT07217301, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07217301,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07217301